Table 1.
Descriptive characteristics of the study population, by cohort and presence of acute pancreatitis (AP).
| Danish cohort N=12,522 | US cohort N=37,552 | |||
|---|---|---|---|---|
| AP | No AP | AP | No AP | |
| Total | 179 (1.4%) | 12,343 (98.6%) | 2,207 (5.9%) | 35,345 (94.1%) |
| Age, y, median (IQR) | 65 (56–72) | 71 (63–78) | 77 (71–83) | 78 (72–84) |
| Age group | ||||
| ≤65 years | 93 (52.0%) | 3,911 (31.7%) | - | - |
| 66–70 years | 27 (15.1%) | 2,188 (17.7%) | 479 (21.7%) | 6,438 (18.2%) |
| 71–75 years | 25 (14.0%) | 2,199 (17.8%) | 481 (21.8%) | 7,306 (20.7%) |
| >75 years | 34 (19.0%) | 4,045 (32.8%) | 1,247 (56.5%) | 21,601 (61.1%) |
| Sex | ||||
| Men | 97 (54.2%) | 6,216 (50.4%) | 977 (44.3%) | 15,994 (45.2%) |
| Women | 82 (45.8%) | 6,127 (49.6%) | 1,230 (55.7%) | 19,351 (54.8%) |
| Race | ||||
| White | - | - | 1,730 (78.4%) | 29,307 (82.9%) |
| African-American | - | - | 270 (12.2%) | 3,306 (9.4%) |
| Hispanic | - | - | 95 (4.3%) | 1,181 (3.3%) |
| Other | - | - | 112 (5.1%) | 1,551 (4.4%) |
| Gagne Comorbidity score | ||||
| Low (≤0) | 133 (74.3%) | 9,718 (78.7%) | 311 (14.1%) | 11,972 (33.9%) |
| Moderate (1–2) | 39 (21.8%) | 2,186 (17.7%) | 605 (27.4%) | 10,319 (29.2%) |
| Severe (>2) | 7 (3.9%) | 439 (3.6%) | 1,291 (58.5%) | 13,054 (36.9%) |
| Comorbidity | ||||
| Alcohol-related disease | 13 (7.3%) | 221 (1.8%) | 145 (6.6%) | 964 (2.8%) |
| Smoking-related disease | 18 (10.1%) | 705 (5.7%) | 1,251 (56.7%) | 13,383 (37.9%) |
| Cholecystitis | ≤52 (−) | 165 (1.3%) | 721 (32.7%) | 5,103 (14.4%) |
| Cholangitis | ≤52 (−) | 291 (2.4%) | 196 (8.9%) | 1,165 (3.3%) |
| Frailty | ||||
| Low | - | - | 789 (35.8%) | 15,909 (45.0%) |
| Moderate | - | - | 826 (37.4%) | 12,270 (34.7%) |
| High | - | - | 592 (26.8%) | 7,166 (20.3%) |
| Period of diagnosis | ||||
| 2004–2007 | 35 (19.6%) | 3,291 (26.7%) | 875 (39.7%) | 14,107 (39.9%) |
| 2008–2011 | 43 (24.0%) | 3,613 (29.3%) | 709 (32.1%) | 10,612 (30.0%) |
| 2012–20161 | 101 (56.4%) | 5,439 (44.1%) | 623 (28.2%) | 10,626 (30.1%) |
| Tumor site | ||||
| Head | 89 (51.0%) | 4,731 (38.3%) | 1,389 (62.9%) | 16,781 (47.5%) |
| Body | ≤102 (−) | 960 (7.8%) | 168 (7.6%) | 3,830 (10.8%) |
| Tail | ≤102 (−) | 663 (5.4%) | 131 (5.9%) | 3,987 (11.3%) |
| Other | 14 (6.5%) | 651 (5.3%) | 519 (23.5%) | 10,747 (30.4%) |
| Unknown | 66 (36.9%) | 5,338 (43.2%) | - | - |
| AJCC stage | ||||
| Stage I | 13 (7.3%) | 430 (3.5%) | 231 (10.5%) | 2,630 (7.4%) |
| Stage II | 31 (17.3%) | 1,387 (11.2%) | 627 (28.4%) | 7,553 (21.4%) |
| Stage III | 17 (9.5%) | 1,157 (9.4%) | 167 (7.6%) | 2,538 (7.2%) |
| Stage IV | 76 (42.5%) | 6,015 (48.7%) | 759 (34.4%) | 16,211 (45.9%) |
| Unknown | 42 (23.5%) | 3,354 (27.2%) | 423 (19.2%) | 6,413 (18.1%) |
| Treatment | ||||
| Best supportive care | 79 (44.1%) | 6,396 (51.8%) | 1,212 (54.9%) | 19,204 (54.3%) |
| Oncological treatment | 64 (35.8%) | 4,456 (36.1%) | 639 (30.0%) | 12,140 (34.4%) |
| Resection +/−oncological | 36 (20.1%) | 1,491 (12.1%) | 356 (16.1%) | 4,001 (11.3%) |
1
2012–2013 for the US cohort.
2
Numbers collapsed for confidentiality purposes.